LNTH
Lantheus Holdings, Inc.
$104.52
+0.19%
$6.8B
No data for this timeframe.
Vol
Market Cap$6.8B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (84%)
Inst. Holders50 funds
Inst. Value$3.8B
Inst. Activity25 buys / 17 sells
SEC Reports4
Press Releases1
Exchange Nasdaq·Sector In Vitro & In Vivo Diagnostic Substances·Inc. DE·CIK 0001521036·Prev Close $104.32
Recent Activity
Aug 13, 2026
fda_pdufa
PDUFA: LNTH — MK-6240 in Unknown — 2026-08-13
FDA target action date 2026-08-13 for LNTH (Lantheus Holdings, Inc.). Drug: MK-6240. Indication: Unk
Jun 2, 2026
SEC
Lantheus announced that an image from its LNTH-2513 (18F-GP1) PET/CT trial for deep vein thrombosis (DVT) was awarded SN
PRESS-RELEASE — Impact 4/10
May 14, 2026
Insider
Heino Mary Anne surrendered for taxes 1,227 shares
Executive Chair and CEO @ $96.67 ($118.6K)
May 14, 2026
Insider
Ber Gerard surrendered for taxes 381 shares
Director @ $96.67 ($36.8K)
May 14, 2026
Insider
Morrow Phuong Khanh was granted 4,137 shares
Director
May 7, 2026
SEC
Lantheus reported Q1 2026 revenue of $377.3M (beat consensus $354.4M) and adjusted EPS of $1.46 (beat $1.23), but adjust
8-K — Impact 6/10
Mar 20, 2026
SEC
Lantheus Holdings, Inc. (LNTH) has filed a definitive proxy statement (DEFA14A) for its 2026 Annual Meeting of Stockhold
DEFA14A — Impact 4/10
Inst.
TD ASSET MANAGEMENT INC — ADD
1,133,518 shares ($86.0M)
Price Targets
$105.23
+0.7% upside
Hold
Current $104.52
Low $76.00
Median $106.00
High $117.00
13 analysts
$76.00
$117.00
Analyst Ratings
5Strong Buy
11Buy
3Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 27, 2026 | Mizuho | MAINTAIN | Outperform → Outperform |
| May 11, 2026 | Truist Securities | REITERATE | Buy → Buy |
| May 8, 2026 | Citizens | MAINTAIN | Market Outperform → Market Outperform |
| May 8, 2026 | Mizuho | MAINTAIN | Outperform → Outperform |
| Apr 15, 2026 | Truist Securities | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $1.30 ▲ +3.7% | $1.16 — $1.53 | -17% YoY | 11 |
| Next Q | $1.30 | $1.21 — $1.58 | 2% YoY | 11 |
| Current FY | $5.33 ▲ +3.2% | $4.87 — $6.05 | -12% YoY | 14 |
| Next FY | $6.40 ▲ +1.6% | $5.79 — $7.35 | 20% YoY | 13 |
Latest Reports
NEUTRAL
PRESS-RELEASE
4/10
Lantheus announced that an image from its LNTH-2513 (18F-GP1) PET/CT trial for deep vein thrombosis (DVT) was awarded SN
Jun 2, 2026
MIXED
8-K
6/10
Lantheus reported Q1 2026 revenue of $377.3M (beat consensus $354.4M) and adjusted EPS of $1.46 (beat $1.23), but adjust
May 7, 2026
NEUTRAL
Press
5/10
Lantheus Holdings received FDA approval for PYLARIFY TruVu, a new formulation of its leading PSMA PET imaging agent for
Mar 6, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BlackRock, Inc. | $620.7M | — |
| FARALLON CAPITAL MANAGEMENT LLC | $423.5M | ADD |
| JANUS HENDERSON GROUP PLC | $362.2M | — |
| FMR LLC | $350.9M | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $240.8M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 14, 2026 | Heino Mary | F | $118.6K |
| May 14, 2026 | Ber Gerard | F | $36.8K |
| May 14, 2026 | Morrow Phuong | A | $0.00 |
| May 14, 2026 | McHugh Julie | A | $0.00 |
| May 14, 2026 | EASTLAND JULIA | A | $0.00 |
50 institutional holders with $3.8B total value (50,692,293 shares) as of 2026-Q1. Top holders: BlackRock,, FARALLON, JANUS. Net buying activity: 25 institutions added/increased vs 17 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 8,183,193 | $620.7M | 16.1% | — |
| 2 | FARALLON CAPITAL MANAGEMENT LLC | 5,583,479 | $423.5M | 11.0% | ADD +56.1% |
| 3 | JANUS HENDERSON GROUP PLC | 4,774,841 | $362.2M | 9.4% | — |
| 4 | FMR LLC | 4,626,453 | $350.9M | 9.1% | — |
| 5 | VANGUARD PORTFOLIO MANAGEMENT LLC | 3,174,274 | $240.8M | 6.3% | — |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 2,914,314 | $221.1M | 5.8% | — |
| 7 | STATE STREET CORP | 2,429,803 | $184.3M | 4.8% | — |
| 8 | MORGAN STANLEY | 1,646,463 | $124.9M | 3.2% | TRIM -54.7% |
| 9 | DIMENSIONAL FUND ADVISORS LP | 1,379,570 | $104.6M | 2.7% | — |
| 10 | Swedbank AB | 1,228,743 | $93.2M | 2.4% | — |
| 11 | TD ASSET MANAGEMENT INC | 1,133,518 | $86.0M | 2.2% | ADD +59.2% |
| 12 | Point72 Asset Management, L.P. | 974,210 | $73.9M | 1.9% | NEW |
| 13 | NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 840,417 | $63.7M | 1.7% | — |
| 14 | WELLINGTON MANAGEMENT GROUP LLP | 768,850 | $58.3M | 1.5% | DOUBLED +560.7% |
| 15 | MACKENZIE FINANCIAL CORP | 714,561 | $54.2M | 1.4% | ADD +31.1% |
| 16 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 657,413 | $49.9M | 1.3% | — |
| 17 | Epoch Investment Partners, Inc. | 649,751 | $49.3M | 1.3% | ADD +59.4% |
| 18 | MARSHALL WACE, LLP | 611,747 | $46.4M | 1.2% | DOUBLED +162.9% |
| 19 | HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 598,857 | $45.4M | 1.2% | DOUBLED +686.1% |
| 20 | GOLDMAN SACHS GROUP INC | 555,577 | $42.1M | 1.1% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| TD ASSET MANAGEMENT INC | ADD | 711,894 | 1,133,518 | +59.2% | $86.0M | 2026-Q1 |
| WELLINGTON MANAGEMENT GROUP LLP | DOUBLED | 116,374 | 768,850 | +560.7% | $58.3M | 2026-Q1 |
| Epoch Investment Partners, Inc. | ADD | 407,529 | 649,751 | +59.4% | $49.3M | 2026-Q1 |
| MARSHALL WACE, LLP | DOUBLED | 232,677 | 611,747 | +162.9% | $46.4M | 2026-Q1 |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | DOUBLED | 76,179 | 598,857 | +686.1% | $45.4M | 2026-Q1 |
| BALYASNY ASSET MANAGEMENT L.P. | DOUBLED | 140,781 | 539,382 | +283.1% | $40.9M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | TRIM | 819,803 | 531,646 | -35.1% | $40.3M | 2026-Q1 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | NEW | — | 346,755 | — | $26.3M | 2026-Q1 |
| VOYA INVESTMENT MANAGEMENT LLC | DOUBLED | 40,696 | 336,987 | +728.1% | $25.6M | 2026-Q1 |
| Alyeska Investment Group, L.P. | NEW | — | 305,549 | — | $23.2M | 2026-Q1 |
| SILVERCREST ASSET MANAGEMENT GROUP LLC | TRIM | 416,328 | 292,806 | -29.7% | $22.2M | 2026-Q1 |
| VICTORY CAPITAL MANAGEMENT INC | DOUBLED | 84,641 | 269,496 | +218.4% | $20.4M | 2026-Q1 |
| ExodusPoint Capital Management, LP | NEW | — | 216,322 | — | $16.4M | 2026-Q1 |
| FRED ALGER MANAGEMENT, LLC | NEW | — | 136,254 | — | $10.3M | 2026-Q1 |
| Assenagon Asset Management S.A. | ADD | 71,943 | 132,319 | +83.9% | $10.0M | 2026-Q1 |
| Russell Investments Group, Ltd. | ADD | 74,214 | 131,544 | +77.2% | $10.0M | 2026-Q1 |
| SEI INVESTMENTS CO | DOUBLED | 18,096 | 85,350 | +371.7% | $6.5M | 2026-Q1 |
| FIRST TRUST ADVISORS LP | DOUBLED | 15,545 | 60,258 | +287.6% | $4.6M | 2026-Q1 |
| Verition Fund Management LLC | TRIM | 87,500 | 60,000 | -31.4% | $4.6M | 2026-Q1 |
| STIFEL FINANCIAL CORP | TRIM | 59,969 | 43,311 | -27.8% | $3.3M | 2026-Q1 |
| ASSETMARK, INC | NEAR_EXIT | 118,300 | 22,495 | -81.0% | $1.7M | 2026-Q1 |
| FIFTH THIRD BANCORP | DOUBLED | 561 | 17,054 | +2939.9% | $1.3M | 2026-Q1 |
| Vident Advisory, LLC | TRIM | 44,763 | 16,680 | -62.7% | $1.3M | 2026-Q1 |
| TORONTO DOMINION BANK | DOUBLED | 12 | 14,311 | +119158.3% | $1.1M | 2026-Q1 |
| PRUDENTIAL FINANCIAL INC | DOUBLED | 5,145 | 11,300 | +119.6% | $857.1K | 2026-Q1 |
15 unique insiders with 25 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 14, 2026 | Heino Mary Anne | Executive Chair and CEO | TAX W/H | 1,227 | $96.67 | $118.6K |
| May 14, 2026 | Ber Gerard | Director | TAX W/H | 381 | $96.67 | $36.8K |
| May 14, 2026 | Morrow Phuong Khanh | Director | AWARD | 4,137 | — | — |
| May 14, 2026 | McHugh Julie | Director | AWARD | 4,137 | — | — |
| May 14, 2026 | EASTLAND JULIA MARIE | Director | AWARD | 4,137 | — | — |
| May 14, 2026 | LENO SAM R | Director | AWARD | 4,137 | — | — |
| May 14, 2026 | Pruden Gary J | Director | AWARD | 4,137 | — | — |
| May 14, 2026 | Baylor-Henry Minnie | Director | AWARD | 4,137 | — | — |
| May 14, 2026 | Ber Gerard | Director | AWARD | 4,137 | — | — |
| May 14, 2026 | Thrall James H | Director | AWARD | 4,137 | — | — |
| May 14, 2026 | Maeusli Heinz Christoph | Director | AWARD | 4,137 | — | — |
| Apr 17, 2026 | Niedzwiecki Daniel | See Remarks | TAX W/H | 1,911 | $83.82 | $160.2K |
| Mar 5, 2026 | Morgan Amanda Michelle | Chief Commercial Officer | AWARD | 26,208 | — | — |
| Mar 5, 2026 | Morgan Amanda Michelle | Chief Commercial Officer | TAX W/H | 595 | $76.31 | $45.4K |
| Mar 5, 2026 | Niedzwiecki Daniel | See Remarks | TAX W/H | 1,283 | $76.31 | $97.9K |
| Mar 5, 2026 | Niedzwiecki Daniel | See Remarks | AWARD | 36,692 | — | — |
| Mar 5, 2026 | Dinkelborg Ludger | See Remarks | AWARD | 20,966 | — | — |
| Mar 5, 2026 | Marshall Robert J. Jr. | CFO and Treasurer | TAX W/H | 1,182 | $76.31 | $90.2K |
| Mar 5, 2026 | Marshall Robert J. Jr. | CFO and Treasurer | AWARD | 38,002 | — | — |
| Mar 5, 2026 | Brown Kimberly | Chief Accounting Officer | TAX W/H | 133 | $76.31 | $10.1K |
| Mar 5, 2026 | Brown Kimberly | Chief Accounting Officer | AWARD | 6,158 | — | — |
| Mar 2, 2026 | Marshall Robert J. Jr. | CFO and Treasurer | AWARD | 8,491 | — | — |
| Mar 2, 2026 | Morgan Amanda Michelle | Chief Commercial Officer | AWARD | 2,782 | — | — |
| Mar 2, 2026 | Niedzwiecki Daniel | See Remarks | AWARD | 5,169 | — | — |
| Mar 2, 2026 | Heino Mary Anne | Executive Chair and CEO | AWARD | 32,105 | — | — |
4 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 2 mixed, 2 neutral. Avg impact: 5.3/10.
NEUTRAL
PRESS-RELEASE
4/10
Lantheus announced that an image from its LNTH-2513 (18F-GP1) PET/CT trial for deep vein thrombosis
Jun 2, 2026
MIXED
8-K
6/10
Lantheus reported Q1 2026 revenue of $377.3M (beat consensus $354.4M) and adjusted EPS of $1.46 (bea
May 7, 2026
NEUTRAL
DEFA14A
4/10
Lantheus Holdings, Inc. (LNTH) has filed a definitive proxy statement (DEFA14A) for its 2026 Annual
Mar 20, 2026
MIXED
8-K
7/10
Lantheus reported Q4 2025 revenue of $406.8 million (up 4.0% YoY) and full-year 2025 revenue of $1.5
Feb 26, 2026
Current analyst consensus: Strong Buy (84% buy). Based on 19 analysts: 5 strong buy, 11 buy, 3 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$105.23 mean target
+0.7% upside
Hold (1.46)
$76.00 Low
$117.00 High
| Metric | Value |
|---|---|
| Current Price | $104.52 |
| Target Low | $76.00 |
| Target Mean | $105.23 |
| Target Median | $106.00 |
| Target High | $117.00 |
| # Analysts | 13 |
| Recommendation | Hold (1.46) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$1.30 | $1.16 | $1.53 | -17.1% | +3.7% | 5↑ 4↓ | $0.4B | -3.9% | 11 |
| Next Q 2026-09-30 |
$1.30 | $1.21 | $1.58 | 2.1% | -0.4% | 2↑ 9↓ | $0.4B | -5.9% | 11 |
| Current FY 2026-12-31 |
$5.33 | $4.87 | $6.05 | -12.3% | +3.2% | 12↑ 0↓ | $1.5B | -4.9% | 14 |
| Next FY 2027-12-31 |
$6.40 | $5.79 | $7.35 | 19.9% | +1.6% | 10↑ 2↓ | $1.7B | 13.4% | 13 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $1.301 | |
| 7d ago | $1.289 | +0.012 |
| 30d ago | $1.255 | +0.046 |
| 60d ago | $1.262 | +0.039 |
| 90d ago | $1.262 | +0.039 |
4 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 27, 2026 | Mizuho | MAINTAIN | Outperform | Outperform |
| May 11, 2026 | Truist Securities | REITERATE | Buy | Buy |
| May 8, 2026 | Citizens | MAINTAIN | Market Outperform | Market Outperform |
| May 8, 2026 | Mizuho | MAINTAIN | Outperform | Outperform |
| Apr 15, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
| Apr 13, 2026 | Mizuho | MAINTAIN | Outperform | Outperform |
| Mar 2, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
| Feb 27, 2026 | Mizuho | MAINTAIN | Outperform | Outperform |
| Feb 27, 2026 | Citizens | MAINTAIN | Market Outperform | Market Outperform |
| Feb 27, 2026 | Jones Trading | DOWNGRADE | Buy | Hold |
| Feb 24, 2026 | Citizens | MAINTAIN | Market Outperform | Market Outperform |
| Dec 18, 2025 | Truist Securities | MAINTAIN | Buy | Buy |
| Dec 17, 2025 | Mizuho | MAINTAIN | Outperform | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 5 | 11 | 3 | 0 | 0 | 84% | |
| May 1, 2026 | 5 | 11 | 3 | 0 | 0 | 84% | |
| Apr 1, 2026 | 5 | 11 | 3 | 0 | 0 | 84% | |
| Mar 1, 2026 | 5 | 11 | 3 | 0 | 0 | 84% | |
| Feb 1, 2026 | 4 | 12 | 3 | 0 | 0 | 84% | |
| Jan 1, 2026 | 4 | 12 | 3 | 0 | 0 | 84% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Aug 13, 2026
fda_pdufa
PDUFA: LNTH — MK-6240 in Unknown — 2026-08-13
FDA target action date 2026-08-13 for LNTH (Lantheus Holdings, Inc.). Drug: MK-6240. Indication: Unknown. PDUFA target action date set for MK-6240.
Jun 29, 2026
fda_pdufa
PDUFA: LNTH — LNTH 2501 (Ga 68 edotreotide) in somatostatin receptor positive neuroendocrine tumors (NETs) — 2026-06-29
FDA target action date 2026-06-29 for LNTH (Lantheus Holdings, Inc.). Drug: LNTH 2501 (Ga 68 edotreotide). Indication: somatostatin receptor positive
Jun 3, 2026
short_volume
Short Volume: LNTH — 62.7% short (0.3M / 0.5M)
Short: 339,393 | Exempt: 0 | TRF Vol: 540,930 | Short Ratio: 62.7% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
Clinical Trial
Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis
Phase Phase 3 — COMPLETED
Jun 2, 2026
clinical_trial_readout
Results Pending: [18F]florbetaben (Phase 3) — Completed 42d ago
Trial: Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis
Sponsor: Lantheus Germany GmbH
Phase: Phase 3 | Completed: 2026-04-21
Jun 2, 2026
earnings
Lantheus' LNTH-2513 (18F-GP1) PET/CT Awarded SNMMI’s Image of the Year
<p>BEDFORD, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ: LNTH), the leading radiopharmaceutical-focused co
May 27, 2026
other
Lantheus to Present at the William Blair 46th Annual Growth Stock Conference
<p>BEDFORD, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceu
May 21, 2026
routine
Lantheus Highlights New Radiodiagnostic Data at the 2026 SNMMI Annual Meeting
<p>BEDFORD, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused co
May 8, 2026
short_volume
Short Volume: LNTH — 62.2% short (0.4M / 0.6M)
Short: 378,237 | Exempt: 1,291 | TRF Vol: 608,088 | Short Ratio: 62.2% | Off-exchange volume (dark pool + OTC)
May 7, 2026
earnings
Lantheus Reports First Quarter 2026 Financial Results and Provides Business Update
<p>BEDFORD, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus or the Company) (NASDAQ: LNTH), the leading radiopharmaceutica
May 7, 2026
earnings_calendar
LNTH Q1 2026 Earnings Before Market Open — 2026-05-07
May 5, 2026
earnings_calendar
LNTH Q1 2026 Earnings Before Market Open — 2026-05-05
Apr 30, 2026
earnings_calendar
LNTH Q1 2026 Earnings Before Market Open — 2026-04-30
Apr 13, 2026
short_volume
Short Volume: LNTH — 93.6% short (0.6M / 0.6M)
Short: 598,486 | Exempt: 0 | TRF Vol: 639,483 | Short Ratio: 93.6% | Off-exchange volume (dark pool + OTC)
Mar 29, 2026
fda_pdufa
PDUFA: LNTH — OCTEVY in Unknown — 2026-03-29
FDA target action date 2026-03-29 for LNTH (Lantheus Holdings, Inc.). Drug: OCTEVY. Indication: Unknown. PDUFA target action date set for OCTEVY.
Mar 17, 2026
other
Lantheus Announces Three-Month Extension of PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (SSTR+) Neuroendocrine Tumors (NETs)
<p>BEDFORD, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or “Company”) (NASDAQ: LNTH), the leading radiopharmaceuti